Potere Health MD Review

What Potere Health MD charges

• Tirzepatide: $399.99 — for twelve full weeks; the seller restates it as about $135 a month, and its own summary row prints $399 rather than $399.99
• Tirzepatide: $350 — per fill of 60 mg; the page names no period for this tier
• Tirzepatide: $250 — per fill of 60 mg; the same card also prints $299 with nothing to distinguish the two
• Semaglutide: $239.99 — for a supply the seller describes only as "12+ WEEKS", which makes its own restatement of about $80 a month unverifiable
• Semaglutide: $199.99 — per fill of 10 mg; the page names no period for this tier
• Semaglutide: $169.99 — per fill of 10 mg; the page names no period for this tier

A certificate-of-analysis page with no certificate on it

The page carries the headings "Tirzepatide COA", "Semaglutide COA" and "Current Tirzepatide Certificate of Analysis", and the served page contains no document behind any of them.

Its own wording hedges twice: it says it will "provide lot-specific Certificate of Analysis information when available" and that it will "request quality documentation from our pharmacy partners when available".

A heading is not a certificate. No certificate of analysis is reachable here, and none is treated as existing on the strength of that page.

Two prices on one maintenance card

Its third-fill tirzepatide card prints two different figures with no label separating them and nothing saying which applies.

Its summary row and its detail cards also disagree on the cents of the first tirzepatide tier.

Both readings are recorded and the conflict is left exactly as the site leaves it. Its semaglutide ladder carries no such conflict.

Milligrams, not months

Each tier buys a stated quantity of drug — "Another 60 mg of medication" on the tirzepatide ladder — and only the first tier of each ladder carries a supply length.

The seller's own monthly restatement of the first tirzepatide tier is arithmetically consistent with its own numbers; the semaglutide one divides a supply the page describes only as "12+ WEEKS", and that plus sign makes the divisor indeterminate.

The titration schedule is printed beside every tier, so a reader can see which doses the quantity is meant to cover.

One state, and one piece of scoping done right

It says "In-clinic or telehealth visits available throughout Utah" and publishes pages for four Utah towns, so the footprint is one named state.

Its efficacy figures are attributed to the approved drugs rather than to its own compounded ones: "Clinical trials of FDA-approved semaglutide and tirzepatide show average weight loss of 15-21%." That scoping is rarer than it should be.

Its compounding statement is equally direct — "*Compounded semaglutide and tirzepatide are not FDA-approved, are not generic versions of FDA-approved drugs like Ozempic, Wegovy, Mounjaro, or Zepbound, and are not reviewed by FDA for safety, effectiveness, or quality" — and it names no dispensing pharmacy.

How we verified this

• Read the certificate page in full, confirmed the served page carries headings and no document behind them, and recorded a testing claim rather than a certificate.
• Recorded both figures printed on the third-fill tirzepatide card, and both versions of the first tier from the summary row and the detail card, without choosing between them.
• Checked the seller's own monthly restatements against its own stated quantities, and marked the semaglutide one unverifiable because its supply length carries a plus sign.
• Requested a deliberately meaningless address on this host in the same session and confirmed it returns a not-found response.
• Screened the brand under its short, medium and full names against the live federal warning-letter table, pulling all 3,677 records in pages and filtering locally because the table's own search parameter is ignored, through a matcher that normalises both the query and the filed company name before comparing, with a positive and a nonsense control in the same run.